Management team

Christina Herder

Interim CEO from 1 September

Christina Herder has 25 years of experience in early phase drug development and business development in the pharmaceutical industry. Her previous assignments include several senior roles in among other Swedish Orphan Biovitrum AB (Sobi) and Biovitrum. Christina was earlier employed as Executive Vice President, Strategic Business Development at Medivir AB, (listed on Nasdaq, Stockholm). Previous to that Christina was the CEO of Modus Therapeutics, a Swedish drug development company. Since 2015 she has been a member of the Board of PCI Biotech Holding ASA (listed on Oslo Axess). Christina Herder holds a doctorate from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm University.

Holdings: 62,718 shares

Warrant TO5: 99,000

Independent in relation to the Company and its management and the Company´s major shareholders.

Ingvar Karlsson

CFO since 2016

Ingvar Karlsson has a broad experience from qualified positions in several large companies. Most recently Ingvar was CFO of Lekolar Group, before that, he was CFO of Doro AB, which is listed on the NASDAQ OMX Nordic Exchange Small Cap List in Stockholm. Ingvar has also held positions as controller at the Gambro Group and as CFO and controller of Perstorp AB. Ingvar Karlsson holds a M.Sc. in Economics and Business from Lund University.

Holdings: 349,383 shares

Warrant TO5: 496,080

Warrants (2020/2023): 30,000

Warrants (2021/2024): 60,000

Warrants (2022/2025): 250,000

Hanjing Xie

CMO since 2022

Hanjing Xie is a medical doctor and triple Board-certified in hematology, clinical oncology and internal medicine. She has over 25 years of clinical experience mostly from Karolinska University Hospital and she is still clinical active. She has also a PhD in clinical pharmacology from Karolinska Institute (2004) and is an associate professor in oncology at Karolinska Institute.

Hanjing has been active in the pharmaceutical industry since 2015 and has held a number of meritorious senior positions in the pharmaceutical industry such as Senior Medical Advisor at Bayer (2015-2018), Head of the Cancer Clinical Trial Unit at Capio St. Göran’s Hospital (2018-2020), and Senior Medical Study Director at Oncopeptides (2020-2022).

Hanjing Xie contributes with extensive experience and solid knowledge in hematology, clinical treatment with novel immunotherapy/cell therapy in oncology, as well as broad experience in clinical development inclusive conducting clinical trials from early to later phases (I-IV), engagement as medical expert in communication with regulatory authorities (FDA, EMA, MPA, NoMA, DMA), strategic planning of product launch and reimbursement applications.

Holdings:

Warrants (2022/2025): 250,000

Dennis Henriksen

CTO since 2015

Dennis Henriksen joined Idogen in 2014. He has over 20 years managerial industry experience in small to medium size biotechnology companies, including several years in the United States as Vice President of BioNebraska Inc. where he also served as a member in the corporate management group and was responsible for R&D. Dennis has long experience of developing and implementing cGMP in small to medium size biotech companies and has been involved in research and development programs within many different fields, including arthritic diseases, inflammatory and autoimmune diseases and several forms of cancer. Dennis Henriksen holds a M.Sc. in chemical engineering from the Technical University of Copenhagen and a Ph.D. in bioorganic chemistry from the University of Copenhagen.

Holdings: 12,343 shares

Rory Graham

CRO since 2022

Rory has 30 years experience in the regulatory field across Europe, US, and Asia-Pacific in the biotechnology, pharmaceutical and medtech industries in roles with SME’s, large multinational companies and leading consultancy practices. He has worked across all stages of the development cycle and has extensive marketing authorisation approval experience with all the major global regulatory agencies. Rory’s experience working with cell-based products dates back to the late 1990’s and has continued to the present day. In addition to development work he has successfully developed regulatory teams supporting large scale biological manufacturing plants for global supply, and lifecycle management.  Rory holds a degree in pharmacy from Queens University, Belfast, and an MBA from London Business School.

Holdings:

Warrants (2022/2025): 150,000

Martina Johannesson

Cell Therapy Program Manager since 2022

Martina Johannesson has 15 years of experience in cell therapy and stem cell-research.

Martina has worked at two cell therapy companies, namely Xintela as a project leader and recently Amniotics as preclinical development manager. These companies have established GMP-facilities and Martina has thereby knowledge and education in GMP for development of cell therapy products. She has been the link between small scale developmental work in R&D and upscaling processes according to GMP for clinical studies.

Moreover, Martina has worked as a QA-coordinator at the medical technology company VitroSorb, Medical Writer at the National Board of Health and Welfare, and Research Scientist at Camurus.

Martina has a PhD in human embryonic stem cell-research at the University of Lund, Sweden, did her post doc at Novo Nordisk, Denmark, and has education in GCP and writing of clinical study reports.

Holdings: – shares